Boston Scientific stock enters November with results and WATCHMAN update

Published on 11/07/2026 at 11:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock enters November after third-quarter results and a positive WATCHMAN study update. A healthcare conference is next.

Results And Pipeline Takeaways

Boston Scientific released its third-quarter 2026 results on October 28.
The SIMPLAAFY study of the WATCHMAN FLX Pro device met its primary endpoints on November 2.
The company is scheduled to participate in Stifel's 2026 Healthcare Conference on November 11.

Boston Scientific, US1011371077, Illustration mit AI erstellt.

Boston Scientific entered the week with two developments for investors: its third-quarter results and a clinical update for the WATCHMAN FLX Pro device. The company published both announcements on its official press release page.

Quarterly Results Set The Backdrop

Boston Scientific announced its third-quarter 2026 results on Wednesday, October 28. The release provides the latest operating update before the company’s next scheduled investor appearance and keeps execution across its medical-device portfolio in focus.

WATCHMAN Study Adds Pipeline Support

On Monday, November 2, Boston Scientific said the SIMPLAAFY study of the WATCHMAN FLX Pro left atrial appendage closure device met its primary endpoints. The update concerns post-implant treatment options and supports the company’s effort to broaden the clinical evidence around the WATCHMAN platform.

For investors, the study update adds a longer-term product-development angle to the recent quarterly report. Clinical evidence can influence adoption discussions, while commercial execution remains central to the company’s near-term investment case.

Next Investor Date

Boston Scientific is scheduled to participate in Stifel’s 2026 Healthcare Conference on Wednesday, November 11. The event is the next stated company appearance for investors following the quarterly release and the WATCHMAN update.

Boston Scientific stock traded at 38.39 euros on Lang & Schwarz at 11:02 CET on Saturday, November 7, 2026. Investors can follow the real-time quote of Boston Scientific stock.

The broader US market remains the relevant benchmark for the company, with updates available through the S&P 500 market reports.

More developments can be found in more news and analyses on Boston Scientific stock.